Schoenherr has advised Sanofi on the acquisition of 100% of the shares in Origimm Biotechnology GmbH. Binder Groesswang and, reportedly, Squire Patton Boggs’ Frankfurt office advised the sellers on the deal.
Sanofi is a global life sciences company. Origimm – Origins of Immunity – is an Austrian biotech company with expertise in the discovery of vaccine antigens and drug targets for the prevention and treatment of diseases and infections associated with skin-colonizing microbes.
Schoenherr’s team included Partners Roman Perner, Michael Woller, and Christoph Haid, Counsels Teresa Waidmann and Stefanie Aichhorn-Woss, Attorneys Michael Marschall and Marco Thorbauer, and Associates Alexander Pabst, Daniel Komarek, and Daniel Neuwirth-Riedl.
Binder Groesswang’s team included Partners Thomas Schirmer, Ivo Rungg, Clemens Willvonseder, and Johannes Barbist, Counsel Hellmut Buchroithner, and Attorneys Mona Holzgruber and Regina Kroll.
Editor's note: After this article was published, Binder Groesswang announced that it advised Sanja Selak – founder, co-shareholder, and managing director of Origimm.